Under the agreement, Pear will license a digital therapeutic developed by Cincinnati Children’s to treat migraine headaches. The therapeutic uses cognitive behavioral therapy and patient education, and was evaluated by the hospital in a recently completed clinical trial.
Other additions to Pear’s prescription digital therapeutics platform stem from new licensing, acquisition and development agreements with Firsthand Technology, the Karolinska Institute in Sweden, Winterlight Labs and NeuroLex Laboratories. The collaborations will allow the startup to develop new digital therapeutics to treat a variety of illnesses and further improve its existing software-based treatments, Pear CEO and President Corey McCann, MD, PhD, said in the announcement.
More articles on health IT:
AHA, OSF HealthCare join $25M funding for social determinants software
Providence CIO: Healthcare must overcome ‘technical debt’ to expand innovation
Minnesota hospital warns nearly 50,000 patients of data breach
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.